Lilly’s 2021 Double-Digit Growth Comes From COVID-19 Drugs, New Products

Prevail Purchase For $880m Adds Gene Therapy Capabilities

 
• By Mandy Jackson
  
Business man showing pie chart in color background
Lilly forecasts growth across its portfolio of newer commercial products
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Business

More from Scrip